EMA Pushes For Industry Collaboration On Psychiatric And Psychedelic Drug Innovations

The European Medicines Agency wants to work with other regulators as well as industry, scientists and patients to “find solutions for the most pertinent problems in psychedelic research” and improve treatment options for psychiatric disorders more broadly, says the agency.

(Shutterstock)

More from R&D

More from Pathways & Standards